Anti-West Nile Virus (Clone: WNV-99)

B cells were isolated and sequenced from an individual previously infected with a laboratory-confirmed, symptomatic WNV infection whose serum reacted to recombinant WNV NS1².

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.

Standard Overnight on Blue Ice.

ELISA
FC

WNV-99 activity is directed against the wing, flexible loop of NS1. During the screening phase and post characterization clone WNV-99 was found to bind to solid-phase recombinant WNV NS1 protein and to NS1 expressed on the surface of intact WNV-infected Vero cells. Plus, also engaged the hexameric form of NS1. WNV-99 was cross-reactive against Japanese Encephalitis Virus and Tick-borne Encephalitis Virus in a direct ELISA using recombinant NS1 proteins.

West Nile Virus (WNV) is a mosquito-borne, enveloped, positive-stranded RNA flavivirus¹. Flavivirus nonstructural protein NS1 has been proposed as an antibody target to avoid antibody-dependent enhancement². NS1 is a 46-55 kDa glycoprotein that is expressed as a dimer on the cell surface and as a soluble hexamer in the extracellular space and in circulation during infection. WNV NS1 dimer consists of a ß-roll, wing, and ß-ladder.

1. Goo L, Debbink K, Kose N, et al. Nat Microbiol. 4(1):71-77. 2019.
2. Wessel AW, Doyle MP, Engdahl TB, et al. mBio. 12(5):e0244021. 2021.